COHERUS BIOSCIENCES I

Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day Event

22 Mar 2022 16:30:24 By Nasdaq GlobeNewswire

Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer

15 Mar 2022 08:00:02 By Nasdaq GlobeNewswire

Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series

15 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

Coherus Management to Present at Upcoming Investor Conferences

04 Mar 2022 16:05:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell

04 Mar 2022 08:00:00 By Nasdaq GlobeNewswire

Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results

17 Feb 2022 16:01:00 By Nasdaq GlobeNewswire

Coherus Names Paul Reider Chief Commercial Officer

15 Feb 2022 16:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

14 Feb 2022 08:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022

11 Feb 2022 08:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences Appoints Health Care Payer Expert Lee N. Newcomer, M.D., to Board of Directors

07 Feb 2022 08:30:01 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody

10 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences Secures Credit Financing with Pharmakon Advisors

07 Jan 2022 08:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 08:32:50 By Nasdaq GlobeNewswire

Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)

20 Dec 2021 07:59:00 By Nasdaq GlobeNewswire

Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer

17 Dec 2021 09:09:17 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

16 Dec 2021 16:30:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

13 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer

15 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

10 Nov 2021 16:15:01 By Nasdaq GlobeNewswire

Coherus BioSciences Reports Third Quarter 2021 Results

08 Nov 2021 16:01:00 By Nasdaq GlobeNewswire